Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Background: Identification of new biomarkers with potential predictive and prognostic role
has contributed unequivocally to breast cancer treatment.
Although traditionally endocrine therapy is based on hormonal receptors status (estrogen - ER
and progesterone- PR), some patients become hormone resistant. In order to identify a
possible profile associated to hormonal resistance, some biomarkers have been assessed after
short period primary hormone therapy (HT).
Objectives: To compare the expression of Ki-67, Bcl2, Bax, Bak, ER and e PR in postmenopausal
women with ER positive invasive ductal carcinomas (IDC), prior and after tamoxifen and
anastrozole in short term hormone therapy.